Significant Ownership of Squadron Capital Management LLC

Signature - Title
/s/ Matthew Sesterhenn - Partner
Location
Hinsdale, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Squadron Capital Management LLC.

Notify me when Squadron Capital Management LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Squadron Capital Management LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RLMD RELMADA THERAPEUTICS, INC. Common Stock ($.001 par value) 9.9% $31,283,007 +$17,330,352 7,395,510 +124% Squadron Master Fund LP 31 Dec 2025
NXTC NextCure, Inc. Common Stock, $0.001 par value per share 9.9% $3,521,940 +$1,263,485 271,127 +56% Squadron Master Fund LP 31 Dec 2025
KTTA Pasithea Therapeutics Corp. Common Stock, par value $0.0001 per share 9.9% $2,050,179 +$67,601 2,329,749 +3.4% Squadron Master Fund LP 31 Dec 2025
LPCN Lipocine Inc. Common Stock, par value $0.0001 per share 9.5% $5,549,100 +$314,100 530,000 +6% Squadron Master Fund LP 31 Dec 2025
TRAW Traws Pharma, Inc. Common Stock, par value $.01 per share 8.9% $1,148,799 +$197,289 713,540 +21% Squadron Master Fund LP 31 Dec 2025
SPRB SPRUCE BIOSCIENCES, INC. Common Stock, par value $0.0001 per share 6.5% $5,705,000 70,000 0% Squadron Master Fund LP 31 Dec 2025
ZNTL Zentalis Pharmaceuticals, Inc. Common Stock,$0.001 par value per share 5.1% $9,376,095 3,676,900 Squadron Master Fund LP 24 Feb 2026
PALI PALISADE BIO, INC. Common Stock, par value $0.01 per share 3% $8,640,000 -$7,200,000 4,500,000 -45% Squadron Master Fund LP 31 Dec 2025

Schedules 13D/G Reported by Squadron Capital Management LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.